<DOC>
	<DOCNO>NCT00344617</DOCNO>
	<brief_summary>To assess use Avastin management serosanguinous maculopathy</brief_summary>
	<brief_title>Off-Label AVASTIN ( BEVACIZUMAB ) For Serosanguinous Maculopathy</brief_title>
	<detailed_description>METHODOLOGY Patients recruit vitreoretinal clinic SNEC . After initial assessment , clinically angiographically , patient counsel regard diagnosis , prognosis management option , include option intravitreal Avastin . Inclusion criterion : 1 . All subfoveal/juxtafoveal CNV PCV ( polypoidal choroidal vasculopathy ) eligible treatment option ( compassionate use ) 2 . CNV PCV lesion fail PDT , conventional argon laser photocoagulation ( salvage use ) 3 . CNV PCV lesion treatable PDT , afford refuse Exclusion criterion : 1 . Patients uncontrolled hypertension ( systolic BP great 150mmHg diastolic BP great 90mmHg 2 . History thrombolic event myocardial infarction cerebral vascular accident 3 . Renal abnormality define establish history chronic renal disease renal failure well patient require dialysis 4 . Recent ( define past 28 day ) plan ( define next 3 month ) surgery . 5 . Coagulation abnormality , include anti-coagulant medication aspirin 6 . Patients peptic ulcer disease 7 . Pregnant lactating female If patient agreeable intravitreal treatment protocol , he/she assess systemically fitness therapy . The serosanguinous maculopathy subtyped angiographic finding predominantly classic ( &gt; 50 % classic component ) lesion , minimally classic ( &lt; 50 % classic component ) lesion , occult lesion polypoidal choroidal vasculopathy ( PCV ) . If patient eligible intravitreal treatment protocol , he/she receive 1mg Avastin intravitreally . This performed aseptic technique . ( See attach 'Intravitreal Injection Protocol ' ) . The injection repeat every 8-10 week total 3 treatment . END OF TREATMENT If central retinal thickness reduce &gt; 50 % , imrpovement/stablisiation vision , adverse effect ( elevation BP ) encounter , treat physician elect withhold Avastin treatment . On review 8 16 week , physician elect perform additional intravitreal Avastin treatment follow arise 1 . Loss VA least 5 letter 2 sequential visit within 2 week , associate increased leakage CNV see angiography OCT 2 . Increase OCT central retinal thickness &gt; 100um 3 . Onset new macular haemorrhage 4 . Development new classic CNV membrane 5 . Ocular outcome measurement 6 . Change baseline VA , i.e . gain loss 5 letter ( 1 line ) , 15 letter ( 3 line ) 30 letter ( 6 line ) Secondary outcome 1 . Change OCT measure central retinal thickness 2 . Correlation change central retinal thickness change VA Once inform consent obtain intravitreal Avastin therapy , patient assess fitness indergo treatment . Baseline systemic &amp; ocular assessment perform . Systemic assessment include blood pressure measurement , electrocardiogram ( ECG ) blood investigation ( full blood count , prothrombin time , partial thromboplastin time , bleed time ) Once deem fit , patient receive Injection 1 intravitreal Avastin ( Refer Intravitreal Injection Protocol ) The patient review 1 week post-injection monthly first 2 month . Investigations visit include logMAR BCVA , biomicroscopy , FFA OCT. At time point 8-10 week , patient undergo Injection 2 . Followed review 1 week post-injection monthly 2 month investigation state . At 16-20 week , patient receive last treatment , Injection 3 , similar post-injection visit investigation . If central retinal thickness reduce &gt; 50 % , imrpovement/stablisiation vision , adverse effect ( elevation BP ) encounter , treat physician elect withhold second and/or third Avastin treatment . Hence , patient receive least 1 injection Avastin maximum 3 injection .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . All subfoveal/juxtafoveal CNV PCV ( polypoidal choroidal vasculopathy ) eligible treatment option ( compassionate use ) 2 . CNV PCV lesion fail PDT , conventional argon laser photocoagulation ( salvage use ) 3 . CNV PCV lesion treatable PDT , afford refuse 1 . Patients uncontrolled hypertension ( systolic BP great 150mmHg diastolic BP great 90mmHg 2 . History thrombolic event myocardial infarction cerebral vascular accident 3 . Renal abnormality ( define establish history chronic renal disease renal failure well patient require dialysis ) . 4 . Recent ( define past 28 day ) plan ( define next 3 month ) surgery . 5 . Coagulation abnormality , include anticoagulant medication aspirin 6 . Patients peptic ulcer disease 7 . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Choroidal neovascularisation</keyword>
	<keyword>Polypoidal choroidal vasculopathy</keyword>
	<keyword>Intravitreal injection</keyword>
	<keyword>Avastin</keyword>
</DOC>